Member Info for MR.Spacetomato

"This message has been filtered, please adjust your filters to view".

Ha, the beautiful Trash Can automatic blocking option here to take away the trash is a great invention. :0)

Great news all together. The door for this massive Asian market is now open.

Polarean’s distribution agreement with Sumtage marks a significant strategic milestone, signaling its first commercial expansion into the Asia-Pacific region. This move diversifies the company's geographic footprint beyond the U.S., reducing dependency on a single market and opening new revenue streams. Sumtage’s established presence and expertise in Taiwan’s medical technology sector enhance the likelihood of successful market penetration.

The partnership also positions Polarean to capitalize on the growing demand for advanced pulmonary diagnostics in Asia, driven by rising incidences of respiratory diseases like COPD, asthma, and lung cancer. Regulatory approval will be a key hurdle, but Sumtage’s local experience may streamline this process. Strong interest from academic medical centers indicates early traction, potentially accelerating adoption once the platform is commercially available.

Overall, this agreement strengthens Polarean’s growth prospects, aligning with its strategy to globalize its innovative Xenon MRI technology while maintaining a strong U.S. focus.

Do we have any TR1? No. Are the major shareholders in place? Yes.

Do I give a rates for fluctuations that are the delight/nightmare of day traders, and delight of MMs? Nope, as I am waiting for the results any medium and long term investors have their yes on.

My shares are in the drawer whilst I enjoy my life.

:0)

Wishing all genuine POLX share holders a great 2025. Our patience should reward us all.

ST

...Christmas!

Damn, this Jacob has been busy. But all I see is:

! This message has been filtered, please adjust your filters to view ! (All in green). :0)

"Mike, if it's Jacob and his merry band of vitriol merchants again, just do what I did—straight to Room 101. Clears up the forum and your day in one swift move."

Merry c

Ah, the classic “skin in the game” concern—fair enough, it’s a reasonable point to raise. But before we grab the torches and pitchforks for Polarean’s BOD, let’s have a closer look.

First off, several directors do hold shares. For instance, Bastiaan Driehuys has nearly 14 million shares (around 1.2%), and even the CEO, Christopher von Jako, holds just shy of 6.3 million (about 0.5%). That’s not pocket change. Others like Kenneth West, Cyrille Petit, and Charles Osborne are also invested, though admittedly, their stakes aren’t earth-shattering. If you're expecting Buffett-style “bet the farm” numbers, you might be disappointed—but then again, insider buying isn’t the only metric of commitment.

Now, the CEO's stake might seem modest, but remember: executive compensation packages often include stock options, performance-based shares, and other incentives that align their interests with shareholders. It’s a long game, not a quick “splash the cash” show. Also, let’s not pretend that owning shares is the only way to demonstrate belief in the product. Strategic leadership, operational focus, and vision—all crucial for driving a company forward—don’t come with a share certificate attached.

So, should you be nervous? Sure, if you’re the kind to lose sleep over every little thing. But personally, I’d say the directors have enough “skin in the game” to signal confidence without overexposing themselves financially. At the end of the day, this is one piece of the puzzle—not the whole picture. Keep your eye on the broader fundamentals, not just the size of someone’s wallet.

ST

Thanks DYM Turbo.

ST

Thanks Jackson. I appreciated your help. Will try.

ST

Jackson, any chance you could put some space between the letters on that link? No the last part.

Thanks in advance

Sorry, I don't take part on Telegram. Will wait for the company's news, i guess.

ST

Well, now, that would mean swallow every he "vitriolled" like a parrot with stammer issues all along, wouldn't it? That's assuming he hasn't done so a while ago. I give it him, he was more persistent than that lonely yellow sweetcorn that refuses to flash down the toilet. Bless.

ST

Polarean Imaging just got FDA clearance for their XENOVIEW® 3T Chest Coil on GE HealthCare MRI systems, and it’s like they’ve gone from playing in the local league to qualifying for the MRI World Cup. Now their tech works on all the big players—GE, Philips, Siemens—which means hospitals across the board can finally get in on this lung diagnostic wizardry.

CEO Christopher von Jako is understandably thrilled. Imagine finally being invited to the cool kids’ table after years of eating alone with your fancy Xenon-129 imaging tech. And it’s not just for show—this stuff is actually helping tackle a massive market of over 500 million people with chronic respiratory disease. So yeah, kind of a big deal.

For investors, this is the kind of news that should make you sit up, grab your wallet, and maybe join their webinar on December 3rd. Polarean’s got the FDA nod, a growing market, and now they’re playing on all the MRI consoles that matter. If you’re not paying attention, someone else is—and they’re probably laughing all the way to the bank.

Super news!!

Good morning to the BB members.

I new here. Just joined the party. What are the odds, Balfour Beatty rolling into Ukraine with their hard hats and high-vis jackets, rebuilding a nation while sipping tea out of their thermos flasks? Seriously though, with all the devastation over there, someone’s going to have to put the roads back together, build schools, hospitals, and whatever else has been blown to bits. So, why not a British firm like Balfour Beatty? Especially considering the UK's “special relationship” with Ukraine – which is basically politician-speak for “we’re best mates when it suits us.”

Think about it. Balfour Beatty has the chops for this sort of thing. They’ve been throwing up bridges and railways like it’s a national sport for decades. And with Ukraine desperate for sustainable, modern infrastructure (the kind that won’t fall apart when you sneeze), they’re a perfect fit. Add in the fact that the UK’s been chummy with Ukraine throughout the whole conflict – sending weapons, wagging fingers at Putin, and giving Zelensky standing ovations every time he pops over – and it’s not hard to imagine British firms getting first dibs on the reconstruction contracts.

For Balfour Beatty, this isn’t just about laying bricks and pouring concrete. It’s a PR goldmine. "Look at us, rebuilding a war-torn nation, being all noble and innovative." And let’s face it, Ukraine’s future infrastructure is going to be all about green energy and clever tech – exactly the kind of stuff Balfour Beatty loves to slap on their brochures. So, what do we reckon? A no-brainer or wishful thinking?

I would appreciate your inputs.

ST

Jacob, you’re at it again—like a stuck record nobody wants to listen to. You’re banging on about doom and gloom while ignoring the actual progress Polarean’s making. Revenue jumps from $100k to $1.1m in a year? Nah, doesn’t matter. FDA expansion to tap into a younger market? Meh. And raising $12.6m in funding to back their growth? Clearly just loose change for "expensive staff hires," right?

And let’s talk about the sellers, shall we? It’s the small guys—day traders, derampers, even wannabe rappers—desperately flipping for pennies on a ridiculous spread. Meanwhile, the big players, the TR1 holders, are nowhere to be seen. Doesn’t that tell you something? They’re not budging, because they know the long game. But here you are, pointing fingers at "Space Ramp Tom" like it’s his fault you’ve got your binoculars fixed on the wrong horizon.

Maybe, just maybe, it’s time to stop obsessing over short-term noise and start looking at the bigger picture. But hey, if you want to keep squawking like the budget parrot of AIM, be my guest. Just don’t act surprised when the rest of us move on to actual substance while you’re still stuck in your loop.

ST

PS: This is my last post to you, as frankly, despite it was amusing replying to you, I am bored now. Ciao.

Oh, it’s shortaway again, bringing the pearls of wisdom. So, apparently, Polx is too skint to run their gas exchange trial, huh? Fascinating take, mate. Considering they bagged $12.6 million in funding this year specifically to get that ball rolling, I’m guessing they didn’t spend it all on champagne and first-class flights. But hey, don’t let facts ruin your narrative—it’s much more dramatic this way.

Jacob,

..mate, we get it. You’re like a Spotify glitch stuck on repeat, hammering the same point until it’s worn thinner than cheap toilet paper. I mean, it’s impressive in a way—your commitment to being a human parrot, squawking the same line over and over. But here’s the thing: at some point, it stops being persuasive and starts being background noise. You’re not driving the point home; you’re just driving people mad. Maybe, just maybe, try saying something new. Mix it up a bit. Otherwise, we’ll all just start skipping the track—your track.

Hi Trojan and thanks for the link.

I went over my notes, and in short, we knew most of it but here are the main points:

Alan Huang’s arrival at Polarean Imaging is like drafting a star player to shake up a team’s strategy. His resume reads like a MedTech all-star: a PhD in biomedical engineering from Johns Hopkins, a decade-plus stint at Philips Healthcare managing a $300 million MRI division, and a career spanning research, marketing, and sales. This is a guy who doesn’t just know the game; he’s rewritten parts of the playbook.

So, what’s his plan to turn Polarean into a revenue juggernaut? First, he’s going all in on the US market. Why? FDA approval and a golden ticket in the form of a reimbursement code. The focus is on upgrading existing customers’ tech—those 21 sites aren’t just clients; they’re stepping stones to bigger clinical adoption. Places like Kansas University Medical Center and Duke University are already on board, proving the model works.

But Huang isn’t stopping there. He’s got his sights set on new sales, zeroing in on high-volume healthcare systems. Imagine walking into 100 hospitals and clinics that could benefit from Polarean’s innovative lung imaging tech—it’s a smart move that could pay off in spades. And then there’s the pièce de résistance: partnerships. Philips is already in the fold, and Siemens and GE are next on his list. He’s presenting Polarean’s tech to GE’s US MRI team this month, aiming to embed the company into the sales DNA of every major MRI player.

The strategy is ambitious, but the risks are real. For now, it’s all about the US, which means international expansion is a big “maybe” until solid partnerships are inked. Plus, convincing hospitals to transition from research to clinical use isn’t exactly a walk in the park—there’s bureaucracy, training, and the slow churn of adoption cycles. And let’s not ignore the competition. Polarean’s tech might be groundbreaking, but rivals in the MRI space won’t sit quietly while this newcomer grabs market share.

Still, the potential is undeniable. Huang’s game plan—focused, aggressive, and backed by experience—has all the makings of a winner. If he can deliver on those three fronts, Polarean could go from being an underdog to a heavyweight contender in medical imaging. The next few months will be critical, and whether this strategy leads to a slam dunk or a stumble is something both the market and investors will be watching closely.

ST

GordonB: "Understood but what’s the timescale? Is it a fast process"?

Alright, let's keep it sharp and snappy:

If the sanctions get lifted, don't expect Evraz to bounce back on the market overnight. First, they’ll need to sort out their books. Problem? They’ve struggled to get an auditor, thanks to those sanctions scaring everyone off. That alone could drag on for months.

Then there’s the red tape: regulators like the FCA and the LSE will want their forms, reports, and assurances before giving the green light to lift the trading suspension. More delays.

Bottom line? Even with the sanctions gone, you’re looking at months before Evraz sees the trading floor again. Think of it as a marathon, not a sprint.

ST

1. Trump's Influence on Peace Initiatives

President-elect Donald Trump's recent communications with German Chancellor Olaf Scholz and Russian President Vladimir Putin suggest a proactive approach toward resolving the Ukraine conflict. While not yet in office, Trump's emphasis on negotiation and deal-making aligns with his historical diplomatic style. His interactions have reportedly encouraged European leaders to pursue peace talks, potentially leading to a de-escalation of hostilities. ​​

2. Putin's Receptiveness

Russian President Vladimir Putin appears optimistic about engaging with Trump, viewing him as a pragmatic negotiator. This perception could facilitate more constructive dialogues between the U.S. and Russia, potentially expediting the peace process in Ukraine. ​​

3. Role of the UK and France

With a potential shift toward peace, the United Kingdom and France may focus on Ukraine's reconstruction efforts. This involvement could open avenues for lucrative contracts in rebuilding infrastructure and revitalizing the Ukrainian economy, benefiting both Ukraine and participating nations.

4. Lifting of Sanctions and Economic Implications

A successful peace agreement would likely lead to the lifting of sanctions imposed on Russia. This development would have significant economic ramifications, including the potential resumption of trading for companies like Evraz plc. Evraz, a major steel and mining firm, has been suspended from trading on the London Stock Exchange since March 2022 due to sanctions. The lifting of these restrictions could allow Evraz to re-enter the market, impacting investors and the broader industry. ​​

Conclusion

The evolving diplomatic engagements spearheaded by President-elect Trump, coupled with positive responses from key global leaders, indicate a possible path toward resolving the Ukraine conflict. This progression holds promise for regional stability and economic recovery, with potential benefits for international relations and global markets.

​​​​